clinical_trials
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Confidence88·multiple reportsImportance90NP-EVT-20261015-C4C681D
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
Read the original at the primary source
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Meghana Keshavan · 10/15/2026, 3:43:15 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —